MediciTech (688202) Daily Market Summary (03-12)

MaticHoleFiller · 2026-03-15T17:48:41+00:00

MEDIWOUND (688202) has a comprehensive score of 58.83 as of March 12, 2026. The main cost shows an upward trend, with significant capital outflows. The short-term resistance level is 71.17 yuan, and the support level is 66.37 yuan. Close attention should be paid to the movement of major capital flows to determine future market trends.

MaticHoleFiller

2026-03-15 17:48:41

Abstract generation in progress

Medici 688202

Date: Thursday, March 12, 2026

58.83 points overall score

Strong

Trend direction

Main force cost analysis

69.05 RMB

Main force cost today
69.63 RMB

5-day main force cost
67.85 RMB

20-day main force cost
63.60 RMB

60-day main force cost

Cycle limit-up/down

In the past year

Limit-up

1 time
Limit-down

0 times

Northbound funds data

Holding volume: 1.5112 million shares	Circulating ratio: 1.23%
Net buy yesterday: -23,400 shares	Increase ratio yesterday: -0.019%
5-day increase ratio: 0.113%	20-day increase ratio: 0.338%

Technical analysis

71.17

Short-term resistance level
66.37

Short-term support level
71.17

Mid-term resistance level
63.84

Mid-term support level

Currently, the short-term trend is not clearly defined; awaiting main capital flow to choose direction.
Currently, the mid-term trend is not clearly defined; awaiting main capital flow to choose direction.

K-line pattern

No special pattern at the moment

Capital flow data for March 12, 2026

Net main capital outflow: 22.0885 million RMB
Represents 10% of total transaction volume
Super-large order net inflow: 1.5915 million RMB
Large order net outflow: 23.68 million RMB
Retail investor net inflow: 967,800 RMB

Related industry/concept sectors

Medical services -1.27%, CRO -0.89%, Shanghai Free Trade Zone -0.62%, AI pharmaceutical (medical) -0.64%, etc.

(Note: The above content is generated by a stock analysis tool for user reference only and should not be used as a basis for trading decisions.)

Risk reminder: The above content reflects the opinions of the author or guest and does not represent any stance of Hexun. It does not constitute any investment advice related to Hexun. Investors should consider the risks associated with investment products based on their own circumstances and consult professional investment advisors if needed before making any investment decisions. Hexun strives but cannot verify the authenticity, accuracy, or originality of the above content and makes no guarantees or promises regarding it.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes